TRDA Entrada Therapeutics, Inc.
Healthcare$6.70+2.13%ClosedMarket Cap: $260.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.01
P/S
44.38
EV/EBITDA
-1.33
DCF Value
$9.48
FCF Yield
-51.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-598.0%
Operating Margin
-3109.3%
Net Margin
-2895.1%
ROE
-51.2%
ROA
-49.5%
ROIC
-55.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $875.0K | 8.0% | $-42.3M | $-39.7M | $— | — |
| Q4 null | $1.3M | 31.8% | $-42.2M | $-39.2M | $— | — |
| FY null | $25.4M | 83.9% | $-156.0M | $-143.8M | $— | — |
| Q3 null | $1.6M | -2276.8% | $-47.1M | $-44.1M | $— | — |
| Q2 null | $1.9M | 100.0% | $-46.8M | $-43.1M | $— | — |
| Q1 null | $20.6M | 100.0% | $-21.8M | $-17.3M | $— | — |
| Q4 null | $37.4M | 100.0% | $-5.9M | $1.1M | $— | — |
| FY null | $210.8M | 100.0% | $47.0M | $65.6M | $— | — |
| Q3 null | $19.6M | 100.0% | $-21.7M | $-14.0M | $— | — |
| Q2 null | $94.7M | 100.0% | $53.4M | $55.0M | $— | — |
| Q1 null | $59.1M | 100.0% | $21.1M | $23.5M | $— | — |
| Q4 2023 | $41.8M | 100.0% | $4.9M | $-9.5M | $-0.29 | — |